- H.C. Wainwright has initiated LAVA Therapeutics ( NASDAQ: LVTX ) with a buy rating saying that the company's Gammabody platform could provide superior results in treating tumors.
- The firm has a $9 price target (~111% upside based on Monday's close).
- Gammabodies are bispecific T cell engagers (bsTCEs) targeting V?9V?2 T cells, the predominant population of ?? (gamma-delta) T cells.
- Analyst Arthur He said the Gammabody platform has advantages including broad antigen recognition, the ability to distinguish healthy tissues from tumor, and activation of pro-inflammatory immune cascades.
- Of LAVA's ( LVTX ) lead candidate, LAVA-051, a CD1d Gammabody, in phase 1/2a study for chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia, He noted that phase 1 data demonstrated early signs of clinical activity in the first two indications and a good safety profile.
- Additional dose-escalation data is expected by the end of the year while phase 2a data from the expansion cohorts is expected in 1H 2023.
- He projects risk-adjusted peak revenues of $391M in 2032.
- Check out why Seeking Alpha contributor BioSci Capital Partners sees LAVA ( LVTX ) as a buy.
For further details see:
LAVA Therapeutics initiated at buy at Wainwright on Gammabodies to treat cancer